Academic collaboration program for Parkinson’s Disease launched by Koneska

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Koneska Neuroscience Collaboration Research Data management Parkinson's disease

Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.

The company that works with evidence-based digital biomarkers announced on August 14 its first collaboration in the Koneska Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its neuroscience toolkit into research programs.

The first collaboration of the KAPP-PD program, with Oregon Health & Science University (OHSU), enables the inclusion of app-and actigraphy-based digital measures and electronic patient reported outcome (ePRO) instruments from Koneksa’s neuroscience toolkit into a study comparing short-acting versus long-acting levodopa in Parkinson’s disease.

The toolkit implements a variety of digital assessments that can be combined to collect data for measures of interest.

The OHSU team, led by Delaram Safarpour, is investigating changes in the neurophysiological correlates of PD with carbidopa-levodopa immediate release compared to long-acting levodopa (Rytary), as well as changes in gait performance at intervals of 30 minutes for a total of four hours during each visit. This research will provide strong support for clinical profiles of short- versus long- acting levodopa in PD corresponding to objective physiological measures.

Martina Mancini, associate professor of neurology, OHSU School of Medicine, said: “We are collaborating with Koneksa to enhance our study’s objectives: We’ll be including smartphone- and actigraphy-based digital measures and electronic patient reported outcome (ePRO) instruments into our study.

“Our lab uses new technologies to better understand and measure motor impairments, with the goal of learning how to better help patients with these conditions. Novel, objective metrics, like those made possible with Koneksa’s technology and toolkit, allow us to expand upon what we’ve been able to do in the clinic.

“In particular, digital at-home measures of daily physical activity, gait and mobility, motor functionality, sleep, and ePRO measures of quality of life all have the potential to uniquely complement OHSU’s in-clinic assessments, offering new and real-world-setting patient insights to support the study’s objectives.”

The Koneksa Academic Partnership Program – Parkinson’s Disease (KAPP-PD) is a structured collaboration between the company and select academic partners that enables researchers to incorporate the neuroscience toolkit into research programs focusing on Parkinson’s disease

“Koneksa is proud to extend our contribution to critical neuroscience research through KAPP-PD, and we’re delighted to get the program underway with our first collaboration,” said John Wagner, chief medical officer at Koneksa.

“These measures will support OHSU in both in-clinic and at-home patient monitoring of critical parameters of interest for this study. We’re committed to helping to get new and better treatments to patients faster, and that’s a vision that OHSU’s Balance Disorders Laboratory shares.”

Researchers gain access to an array of devices that capture key measures objectively and sensitively, as well as training materials for site coordinators and study subjects, a cloud-based platform for real-time monitoring, and industry-leading analytics and patented algorithms. 

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers